Quality of life in patients with pemphigus receiving adjuvant therapy

Clinical and Experimental Dermatology

Volumn 37, Issue 6, 2012, Pages 626-630

  Paradisi, A ^a   Cianchini, G ^a   Lupi, F ^a   Di Pietro, C ^a   Sampogna, F ^a   Didona, B ^a   Pagliarello, C ^a   Tabolli, S ^a   Abeni, D ^a  

^a LABORATORIO DI PATOLOGIA VASCOLARE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; RITUXIMAB;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; CLINICAL ASSESSMENT TOOL; COMORBIDITY; CONTROLLED STUDY; CORTICOSTEROID THERAPY; FEMALE; GENERAL HEALTH QUESTIONNAIRE; HEALTH STATUS; HUMAN; MAJOR CLINICAL STUDY; MALE; PEMPHIGUS; PRIORITY JOURNAL; PSYCHOLOGICAL WELL BEING; QUALITY OF LIFE; SHORT FORM 36; SKINDEX 29;

ADRENAL CORTEX HORMONES; ADULT; AGED; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; PEMPHIGUS; QUALITY OF LIFE; QUESTIONNAIRES; SEVERITY OF ILLNESS INDEX;

EID: 84864127174     PISSN: 03076938     EISSN: 13652230     Source Type: Journal    
DOI: 10.1111/j.1365-2230.2011.04282.x     Document Type: Article

References (17)

1. Bystryn IC, Rudolph JL,. Pemphigus. Lancet 2005; 366: 61-73.
2. Stanley JR,. Therapy of pemphigus vulgaris. Arch Dermatol 1999; 135: 76-8.
3. Chams-Davatchi C, Valikhani M, Daneshpazhooh M, et al. Pemphigus: analysis of 1209 cases. Int J Dermatol 2005; 44: 470-6.
4. Ikeda S, Imamura S, Hashimoto I, et al. History of the establishment and revision of diagnostic criteria, severity index and therapeutic guidelines for pemphigus in Japan. Arch Dermatol Res 2003; 295: S12-16.
5. Ware JE Jr, Sherbourne CD,. The MOS 36-item short form health survey (SF-36). Conceptual framework and item selection. Med Care 1992; 30: 473-83.
6. Apolone G, Mosconi P,. The Italian SF-36 Health Survey. translation, validation and norming. J Clin Epidemiol 1998; 51: 1025-36.
7. Chren MM, Lasek RJ, Sahay AP, Sands LP,. Measurement properties of Skindex-16: a brief quality-of-life measure for patients with skin disease. J Cutan Med Surg 2001; 5: 105-10.
8. Abeni D, Picardi A, Pasquini P, et al. Further evidence of the validity and reliability of the Skindex-29: an Italian study on 2,242 dermatological outpatients. Dermatology 2002; 204: 43-9.
9. Goldberg D,. The Detection of Psychiatric Illness by Questionnaire. London: Oxford University Press, 1972.
10. Picardi A, Abeni D, Pasquini P,. Assessing psychological distress in patients with skin diseases. reliability, validity and factor structure of the GHQ-12. J Eur Acad Dermatol Venereol 2001; 15: 410-17.
11. Paradisi A, Sampogna F, Di Pietro C, et al. Quality-of-life assessment in patients with pemphigus using a minimum set of evaluation tools. J Am Acad Dermatol 2009; 60: 261-9.
12. Cianchini G, Corona R, Frezzolini A, et al. Treatment of severe pemphigus with rituximab: report of 12 cases and a review of the literature. Arch Dermatol 2007; 143: 1033-8.
13. Joly P, Mouquet H, Roujeau JC, et al. A single cycle of rituximab for the treatment of severe pemphigus. N Engl J Med 2007; 357: 545-52.
14. Gupta MA, Gupta AK, Schork NJ, Ellis CN,. Depression modulates pruritus perception: a study of pruritus in psoriasis, atopic dermatitis, and chronic idiopathic urticaria. Psychosom Med 1994; 56: 36-40.
15. Sampogna F, Picardi A, Chren MM, et al. Association between poorer quality of life and psychiatric morbidity in patients with different dermatological conditions. Psychosom Med 2004; 66: 620-4.
16. Renzi C, Picardi A, Abeni D, et al. Association of dissatisfaction with care and psychiatric morbidity with poor treatment compliance. Arch Dermatol 2002; 138: 337-42.
17. Renzi C, Abeni D, Picardi A, et al. Factors associated with patient satisfaction with care among dermatological outpatients. Br J Dermatol 2001; 145: 617-23.